S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:PDLI

PDL BioPharma Competitors

$2.47
0.00 (0.00 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.47
Now: $2.47
$2.47
50-Day Range
$2.47
MA: $2.47
$2.47
52-Week Range
$2.09
Now: $2.47
$3.86
VolumeN/A
Average Volume1.48 million shs
Market Capitalization$282.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.1

Competitors

PDL BioPharma (NASDAQ:PDLI) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying PDLI stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to PDL BioPharma, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

PDL BioPharma (NASDAQ:PDLI) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

PDL BioPharma has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for PDL BioPharma and Amgen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PDL BioPharma0000N/A
Amgen0111402.56

Amgen has a consensus target price of $257.3043, indicating a potential upside of 15.95%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than PDL BioPharma.

Earnings & Valuation

This table compares PDL BioPharma and Amgen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PDL BioPharma$54.76 million5.15$-70,410,000.00$0.288.82
Amgen$23.36 billion5.49$7.84 billion$14.8214.97

Amgen has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares PDL BioPharma and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PDL BioPharmaN/A-10.04%-8.29%
Amgen29.42%95.55%15.52%

Summary

Amgen beats PDL BioPharma on 10 of the 13 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

PDL BioPharma has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for PDL BioPharma and Gilead Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PDL BioPharma0000N/A
Gilead Sciences1111202.46

Gilead Sciences has a consensus target price of $96.0370, indicating a potential upside of 51.89%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than PDL BioPharma.

Earnings & Valuation

This table compares PDL BioPharma and Gilead Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PDL BioPharma$54.76 million5.15$-70,410,000.00$0.288.82
Gilead Sciences$22.45 billion3.54$5.39 billion$6.1410.30

Gilead Sciences has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PDL BioPharma and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PDL BioPharmaN/A-10.04%-8.29%
Gilead Sciences5.48%37.77%12.76%

Summary

Gilead Sciences beats PDL BioPharma on 9 of the 13 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility & Risk

PDL BioPharma has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares PDL BioPharma and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PDL BioPharma$54.76 million5.15$-70,410,000.00$0.288.82
Vertex Pharmaceuticals$4.16 billion12.98$1.18 billion$4.2948.44

Vertex Pharmaceuticals has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for PDL BioPharma and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PDL BioPharma0000N/A
Vertex Pharmaceuticals042212.89

Vertex Pharmaceuticals has a consensus target price of $292.68, suggesting a potential upside of 40.85%. Given Vertex Pharmaceuticals' higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than PDL BioPharma.

Profitability

This table compares PDL BioPharma and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PDL BioPharmaN/A-10.04%-8.29%
Vertex Pharmaceuticals38.51%28.55%20.68%

Summary

Vertex Pharmaceuticals beats PDL BioPharma on 12 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and PDL BioPharma (NASDAQ:PDLI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of PDL BioPharma shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of PDL BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Regeneron Pharmaceuticals and PDL BioPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals061512.77
PDL BioPharma0000N/A

Regeneron Pharmaceuticals presently has a consensus price target of $625.8077, suggesting a potential upside of 39.26%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than PDL BioPharma.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, PDL BioPharma has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and PDL BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.12$2.12 billion$21.4720.93
PDL BioPharma$54.76 million5.15$-70,410,000.00$0.288.82

Regeneron Pharmaceuticals has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and PDL BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
PDL BioPharmaN/A-10.04%-8.29%

Summary

Regeneron Pharmaceuticals beats PDL BioPharma on 12 of the 14 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares PDL BioPharma and Biogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PDL BioPharma$54.76 million5.15$-70,410,000.00$0.288.82
Biogen$14.38 billion2.79$5.89 billion$33.577.85

Biogen has higher revenue and earnings than PDL BioPharma. Biogen is trading at a lower price-to-earnings ratio than PDL BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PDL BioPharma and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PDL BioPharmaN/A-10.04%-8.29%
Biogen35.63%51.00%23.54%

Volatility and Risk

PDL BioPharma has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for PDL BioPharma and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PDL BioPharma0000N/A
Biogen5151202.22

Biogen has a consensus price target of $304.4667, suggesting a potential upside of 15.52%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than PDL BioPharma.

Summary

Biogen beats PDL BioPharma on 9 of the 13 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares PDL BioPharma and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PDL BioPharmaN/A-10.04%-8.29%
Alexion Pharmaceuticals16.32%23.16%14.76%

Risk & Volatility

PDL BioPharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for PDL BioPharma and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PDL BioPharma0000N/A
Alexion Pharmaceuticals017712.36

Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.14%. Given Alexion Pharmaceuticals' higher possible upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than PDL BioPharma.

Valuation and Earnings

This table compares PDL BioPharma and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PDL BioPharma$54.76 million5.15$-70,410,000.00$0.288.82
Alexion Pharmaceuticals$4.99 billion6.54$2.40 billion$9.7415.24

Alexion Pharmaceuticals has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats PDL BioPharma on 14 of the 14 factors compared between the two stocks.


PDL BioPharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$221.91flat$128.17 billion$23.36 billion17.90Dividend Announcement
Analyst Report
Analyst Revision
News Coverage
Gilead Sciences logo
GILD
Gilead Sciences
2.8$63.23flat$79.45 billion$22.45 billion65.19Analyst Downgrade
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$207.79flat$54.02 billion$4.16 billion26.24
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$449.38flat$48.14 billion$7.86 billion16.42
Biogen logo
BIIB
Biogen
1.9$263.57flat$40.15 billion$14.38 billion8.72
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$148.46flat$32.64 billion$4.99 billion34.69Unusual Options Activity
News Coverage
Seagen logo
SGEN
Seagen
1.7$145.45flat$26.35 billion$916.71 million57.26Insider Selling
Decrease in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$121.02flat$20.46 billion$876.29 million-54.76Analyst Upgrade
Insider Selling
Incyte logo
INCY
Incyte
1.9$77.50flat$17.04 billion$2.16 billion-49.36
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.37flat$16.07 billion$219.75 million-17.54
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$76.35flat$13.88 billion$1.70 billion17.47Analyst Revision
Novavax logo
NVAX
Novavax
1.6$158.10flat$10.06 billion$18.66 million-30.29Earnings Announcement
Insider Selling
Analyst Revision
Gap Up
Repligen logo
RGEN
Repligen
1.7$183.21flat$10.03 billion$270.24 million223.43Analyst Report
Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.97flat$8.73 billion$788.10 million99.97Unusual Options Activity
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$51.27flat$7.22 billion$1.12 billion106.81Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.9$160.34flat$7.14 billion$1.45 billion15.17
Exelixis logo
EXEL
Exelixis
1.9$21.31flat$6.65 billion$967.78 million44.40Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.41flat$5.47 billion$195.99 million252.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$90.87flat$4.84 billion$1.11 billion29.22Analyst Upgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$71.51flat$4.31 billion$806.43 million-10.13Analyst Report
High Trading Volume
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.21flat$3.98 billion$36.13 million-85.39Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Gap Up
Alkermes logo
ALKS
Alkermes
1.4$18.21flat$2.90 billion$1.17 billion-39.59Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$4.19flat$2.81 billion$901.90 million-23.28
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.35flat$2.74 billion$182.24 million-9.00Earnings Announcement
Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$141.71flat$2.35 billion$120.28 million-143.14Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.43flat$2.14 billion$638.60 million-10.93Analyst Report
Decrease in Short Interest
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92flat$1.94 billion$48.83 million-14.37
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$112.08flat$1.80 billionN/A-10.12Analyst Report
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.36flat$1.67 billion$82.27 million-20.39
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23flat$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$9.99flat$1.61 billion$428.41 million14.48Insider Buying
Codexis logo
CDXS
Codexis
1.5$20.01flat$1.19 billion$68.46 million-57.17Analyst Upgrade
Innoviva logo
INVA
Innoviva
1.4$11.06flat$1.12 billion$261.02 million5.64
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$25.20flat$997.09 million$3.57 million-11.30Gap Up
BOLT
Bolt Biotherapeutics
1.6$28.78flat$993.54 millionN/A0.00Analyst Report
Analyst Revision
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$17.49flat$959.90 million$227.19 million48.58Insider Selling
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.47flat$959.28 million$35.22 million-6.18
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$4.31flat$923.59 million$150,000.00-6.16Analyst Downgrade
MannKind logo
MNKD
MannKind
1.4$3.38flat$835.39 million$63.04 million-16.09Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$6.66flat$807.09 million$322.07 million-6.34Upcoming Earnings
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$19.33flat$638.20 million$252 million-1.98Analyst Report
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58flat$604.95 million$59.29 million-23.87Earnings Announcement
Analyst Revision
Agenus logo
AGEN
Agenus
1.6$3.16flat$600.87 million$150.05 million-2.90
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.66flat$591.64 million$143.01 million-1.08
Geron logo
GERN
Geron
1.4$1.77flat$549.54 million$460,000.00-5.06Upcoming Earnings
Curis logo
CRIS
Curis
1.3$9.13flat$537.00 million$10 million-11.13Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.43flat$521.13 million$22.27 million-5.11Upcoming Earnings
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.20flat$466.95 million$109.33 million-2.35
XOMA logo
XOMA
XOMA
1.8$35.35flat$389.63 million$18.37 million-31.85Upcoming Earnings
Decrease in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$4.13flat$386.99 million$36.63 million-4.86Analyst Upgrade
High Trading Volume
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.